Aro Biotherapeutics Reports Preliminary Efficacy for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe ...
Dental products company Envista Holdings (NYSE:NVST) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 15% year on year to $750.6 million. Its non-GAAP profit of $0.38 per share was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results